< Back to previous page
Organisation
Digestive Oncology
Division
Main organisation:Department of Oncology
Lifecycle:1 Aug 2022 → Today
Organisation profile:
Digestive Oncology
Keywords:oncology
Disciplines:Oncology
Projects
31 - 40 of 55
- Establishment of CRC mouse models and interference with CD4/DC /CD8 dysfunction to improve colorectal cancer therapyFrom1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- Unraveling of protective innate and adaptive immune responses to SARS-CoV-2 in the setting of HCoV crossreactivityFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Spectral flowcytometry (Cytek Aurora)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- MIMICRY - Modulating Immunity and the Microbiome for effective CRC ImmunotherapyFrom1 Jan 2021 → TodayFunding: BOF - iBOF
- Coevolution of epithelium and immune response in colorectal cancer: comprehensive longitudinal analysis and manipulation of crosstalk leading to exhausted responses in dedicated mouse models.From1 Jan 2021 → 29 Feb 2024Funding: Foundations, funds and other with scientific goal
- Single-cell metatranscriptomics in the human gut microbiotaFrom1 Oct 2020 → 30 Sep 2023Funding: FWO senior postdoctoral fellowship
- OrganID: Organ-derived complex 2D/3D cultures in human diseaseFrom1 Oct 2020 → TodayFunding: FWO Strategic Basic Research (SBO)
- Translational research-oriented technology platform for single cell analysisFrom1 May 2020 → TodayFunding: BOF - scientific equipment program
- Characterization of the phenotypic plasticity of IL17-producing T cells during colorectal cancer development and their interactions with the microbiomeFrom1 Jan 2020 → 31 Dec 2023Funding: FWO research project
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → 1 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 1022
- The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases(2010)
Authors: Eric Van Cutsem
Pages: 212 - 218 - Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of life.(2022)
Authors: Eric Van Cutsem
Pages: 100517 - KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS(2014)
Authors: Eric Van Cutsem
Pages: 5 - 5 - Psychological implications of living with familial adenomatous polyposis(2011)
Authors: Eric Van Cutsem
Pages: 438 - 444 - The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer(2021)
Authors: Eric Van Cutsem
Pages: 727 - + - Different surgical strategies in the treatment of familial adenomatous polyposis: what's the role of the ileal pouch-anal anastomosis ?(2011)
Authors: Albert Wolthuis, Eric Van Cutsem
Pages: 427 - 434 - Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study(2013)
Authors: Eric Van Cutsem
Pages: S482 - S482 - Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer(2021)
Authors: Eric Van Cutsem
Pages: 1705 - 1713 - Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study(2015)
Authors: Eric Van Cutsem
Pages: S333 - S333 - Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer = 70 years(2022)
Authors: Eric Van Cutsem
Pages: 1 - 15